178 related articles for article (PubMed ID: 32575160)
1. PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Smart K; Bröske AM; Rüttinger D; Mueller C; Phipps A; Walz AC; Ries C; Baehner M; Cannarile M; Meneses-Lorente G
Clin Pharmacol Ther; 2020 Sep; 108(3):616-624. PubMed ID: 32575160
[TBL] [Abstract][Full Text] [Related]
2. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
[TBL] [Abstract][Full Text] [Related]
4. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Cassier PA; Italiano A; Gomez-Roca C; Le Tourneau C; Toulmonde M; D'Angelo SP; Weber K; Loirat D; Jacob W; Jegg AM; Michielin F; Christen R; Watson C; Cannarile M; Klaman I; Abiraj K; Ries CH; Weisser M; Rüttinger D; Blay JY; Delord JP
Eur J Cancer; 2020 Dec; 141():162-170. PubMed ID: 33161240
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
[TBL] [Abstract][Full Text] [Related]
7. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Machiels JP; Gomez-Roca C; Michot JM; Zamarin D; Mitchell T; Catala G; Eberst L; Jacob W; Jegg AM; Cannarile MA; Watson C; Babitzki G; Korski K; Klaman I; Teixeira P; Hoves S; Ries C; Meneses-Lorente G; Michielin F; Christen R; Rüttinger D; Weisser M; Delord JP; Cassier P
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33097612
[TBL] [Abstract][Full Text] [Related]
9. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
10. Treatment updates on tenosynovial giant cell tumor.
Palmerini E; Staals EL
Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
[TBL] [Abstract][Full Text] [Related]
11. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
12. Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
Bissinger S; Hage C; Wagner V; Maser IP; Brand V; Schmittnaegel M; Jegg AM; Cannarile M; Watson C; Klaman I; Rieder N; González Loyola A; Petrova TV; Cassier PA; Gomez-Roca C; Sibaud V; De Palma M; Hoves S; Ries CH
Sci Transl Med; 2021 Jun; 13(598):. PubMed ID: 34135110
[TBL] [Abstract][Full Text] [Related]
13. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Brahmi M; Vinceneux A; Cassier PA
Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
[TBL] [Abstract][Full Text] [Related]
14. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS; Katiyar V; Dy P; Singh V
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
[No Abstract] [Full Text] [Related]
16. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
17. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
18. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW; Gomez-Roca C; van Herpen C; Coveler AL; Mahalingam D; Verheul HM; van der Graaf WT; Christen R; Rüttinger D; Weigand S; Cannarile MA; Heil F; Brewster M; Walz AC; Nayak TK; Guarin E; Meresse V; Le Tourneau C
Oncotarget; 2016 Nov; 7(48):80046-80058. PubMed ID: 27507056
[TBL] [Abstract][Full Text] [Related]
20. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]